GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immix Biopharma Inc (NAS:IMMX) » Definitions » ROE %

Immix Biopharma (Immix Biopharma) ROE % : -112.55% (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Immix Biopharma ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Immix Biopharma's annualized net income for the quarter that ended in Dec. 2023 was $-20.36 Mil. Immix Biopharma's average Total Stockholders Equity over the quarter that ended in Dec. 2023 was $18.09 Mil. Therefore, Immix Biopharma's annualized ROE % for the quarter that ended in Dec. 2023 was -112.55%.

The historical rank and industry rank for Immix Biopharma's ROE % or its related term are showing as below:

IMMX' s ROE % Range Over the Past 10 Years
Min: -367.81   Med: -104.35   Max: -52.84
Current: -103.76

During the past 5 years, Immix Biopharma's highest ROE % was -52.84%. The lowest was -367.81%. And the median was -104.35%.

IMMX's ROE % is ranked worse than
76.8% of 1362 companies
in the Biotechnology industry
Industry Median: -44.1 vs IMMX: -103.76

Immix Biopharma ROE % Historical Data

The historical data trend for Immix Biopharma's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immix Biopharma ROE % Chart

Immix Biopharma Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
- - -367.81 -52.84 -104.35

Immix Biopharma Quarterly Data
Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -101.64 -79.58 -114.44 -103.78 -112.55

Competitive Comparison of Immix Biopharma's ROE %

For the Biotechnology subindustry, Immix Biopharma's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Immix Biopharma's ROE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immix Biopharma's ROE % distribution charts can be found below:

* The bar in red indicates where Immix Biopharma's ROE % falls into.



Immix Biopharma ROE % Calculation

Immix Biopharma's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=-15.426/( (13.16+16.405)/ 2 )
=-15.426/14.7825
=-104.35 %

Immix Biopharma's annualized ROE % for the quarter that ended in Dec. 2023 is calculated as

ROE %=Net Income (Q: Dec. 2023 )/( (Total Stockholders Equity (Q: Sep. 2023 )+Total Stockholders Equity (Q: Dec. 2023 ))/ count )
=-20.36/( (19.774+16.405)/ 2 )
=-20.36/18.0895
=-112.55 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. ROE % is displayed in the 30-year financial page.


Immix Biopharma  (NAS:IMMX) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-20.36/18.0895
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-20.36 / 0)*(0 / 21.2)*(21.2 / 18.0895)
=Net Margin %*Asset Turnover*Equity Multiplier
=N/A %*0*1.172
=ROA %*Equity Multiplier
=N/A %*1.172
=-112.55 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-20.36/18.0895
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-20.36 / -20.588) * (-20.588 / -21.504) * (-21.504 / 0) * (0 / 21.2) * (21.2 / 18.0895)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 0.9889 * 0.9574 * N/A % * 0 * 1.172
=-112.55 %

Note: The net income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Immix Biopharma ROE % Related Terms

Thank you for viewing the detailed overview of Immix Biopharma's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Immix Biopharma (Immix Biopharma) Business Description

Traded in Other Exchanges
N/A
Address
11400 West Olympic Boulevard, Suite 200, Los Angeles, CA, USA, 90064
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. It has two business units ImmixBio and Nexcella.
Executives
Jason Hsu director 11400 WEST OLYMPIC BLVD., SUITE 200, LOS ANGELES CA 90064
Carey Ng director 11400 WEST OLYMPIC BLVD., SUITE 200, LOS ANGELES CA 90064
Helen C. Adams director 15378 AVENUE OF SCIENCE, STE 100, SAN DIEGO CA 92128
Melissa Jane Buchan director 1920 MAIN STREET, SUITE 500, IRVINE CA 92614
Magda Marquet director ALTHEADX INC., 3550 DUNHILL STREET, SAN DIEGO CA 92121
Yekaterina Chudnovsky director, 10 percent owner C/O ELICIO THERAPEUTICS, INC., 451 D STREET, 5TH FLOOR, SUITE 501, BOSTON MA 02210
Ilya M Rachman director, officer: CEO and Chairman 11400 WEST OLYMPIC BLVD.,, SUITE 200, LOS ANGELES CA 90064
Gabriel S Morris director, officer: Chief Financial Officer 11400 WEST OLYMPIC BLVD.,, SUITE 200, LOS ANGELES CA 90064
Sean Senn 10 percent owner 11400 WEST OLYMPIC BLVD., SUITE 200, LOS ANGELES CA 90064
Vladimir P Torchilin officer: Scientific Co-Founder 11400 WEST OLYMPIC BLVD.,, SUITE 200, LOS ANGELES CA 90064
Graham Ross officer: CMO & Head of Clinical Dev. 11400 WEST OLYMPIC BLVD., SUITE 200, LOS ANGELES CA 90064

Immix Biopharma (Immix Biopharma) Headlines

From GuruFocus